Longevity Biomedical (Longevity Biomedical) EV-to-EBIT : (As of May. 20, 2024)

View and export this data going back to 2050. Start your Free Trial

What is Longevity Biomedical EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Longevity Biomedical's Enterprise Value is $0.00 Mil. Longevity Biomedical does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Longevity Biomedical's EV-to-EBIT at this moment.

The historical rank and industry rank for Longevity Biomedical's EV-to-EBIT or its related term are showing as below:

LBIO's EV-to-EBIT is not ranked ^*
in the Biotechnology industry.
Industry Median: 9.96
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Longevity Biomedical's Enterprise Value for the quarter that ended in . 20 was $0.00 Mil. Longevity Biomedical does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Longevity Biomedical's Earnings Yield (Joel Greenblatt) % at this moment.

Longevity Biomedical EV-to-EBIT Historical Data

The historical data trend for Longevity Biomedical's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longevity Biomedical EV-to-EBIT Chart

Longevity Biomedical Annual Data

Trend

EV-to-EBIT

Longevity Biomedical Semi-Annual Data

EV-to-EBIT

Competitive Comparison of Longevity Biomedical's EV-to-EBIT

For the Biotechnology subindustry, Longevity Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longevity Biomedical's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's EV-to-EBIT falls into.

Longevity Biomedical EV-to-EBIT Calculation

Longevity Biomedical's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/
	=

Longevity Biomedical (NAS:LBIO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Longevity Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: . 20 )	=	EBIT	/	Enterprise Value (Q: . 20 )
	=		/
	=	%

Longevity Biomedical EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Longevity Biomedical's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Longevity Biomedical (Longevity Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longevity Biomedical Inc (NAS:LBIO) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011

Website

https://www.longevitybiomedical.com

Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.

Longevity Biomedical (Longevity Biomedical) Headlines

No Headlines